We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+5.59%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$908M
AUM Growth
+$52.9M
Cap. Flow
+$30.8M
Cap. Flow %
3.39%
Top 10 Hldgs %
29.34%
Holding
100
New
7
Increased
28
Reduced
31
Closed
12

Top Buys

Rank Stock Value
1
HBNC icon
Horizon Bancorp
HBNC
+$17.6M
2
HCA icon
HCA Healthcare
HCA
+$17.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.66M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$8.58M
5
LLY icon
Eli Lilly
LLY
+$7.22M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24.8M
2
ARRY
Array Biopharma Inc
ARRY
+$14.8M
3
AGN
Allergan plc
AGN
+$13M
4
CI icon
Cigna
CI
+$9.95M
5
WBA
Walgreens Boots Alliance
WBA
+$9.17M

Sector Composition

Rank Sector Weight
1 Healthcare 91.04%
2 Financials 2.97%
3 Industrials 0.36%
4 Technology 0.08%
5 Energy 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
26
Neurocrine Biosciences
NBIX
$16.6B
$15.2M 1.67%
180,000
+2,909
+2% +$239K
CI icon
27
Cigna
CI
$74.6B
$15.2M 1.67%
96,191
-63,500
-40% -$9.95M
MGNX icon
28
MacroGenics
MGNX
$257M
$14.5M 1.6%
857,169
-110,017
-11% -$1.89M
REGN icon
29
Regeneron Pharmaceuticals
REGN
$80.8B
$14.1M 1.55%
45,014
+29,014
+181% +$9.66M
XNCR icon
30
Xencor
XNCR
$1.55B
$13.1M 1.44%
319,792
-6,173
-2% -$203K
ITCI
31
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.3M 1.36%
949,833
– –
COR icon
32
Cencora
COR
$61.2B
$12.1M 1.33%
141,520
+25,000
+21% +$1.98M
IMMU
33
DELISTED
Immunomedics Inc
IMMU
$11.8M 1.3%
851,367
+235,000
+38% +$3.54M
MYOK
34
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$11.3M 1.24%
225,024
– –
LIVN icon
35
LivaNova
LIVN
$4.2B
$10.8M 1.19%
150,000
-90,600
-38% -$6.63M
EXAS
36
DELISTED
Exact Sciences
EXAS
$10.6M 1.17%
90,000
-10,000
-10% -$1.01M
AGIO icon
37
Agios Pharmaceuticals
AGIO
$1.93B
$9.98M 1.1%
200,000
+72,988
+57% +$3.9M
ARNA
38
DELISTED
Arena Pharmaceuticals Inc
ARNA
$9.97M 1.1%
170,000
-64,558
-28% -$3.34M
EXEL icon
39
Exelixis
EXEL
$13.4B
$9.83M 1.08%
460,000
+30,000
+7% +$629K
SGEN
40
DELISTED
Seagen Inc. Common Stock
SGEN
$9.37M 1.03%
135,374
-15,224
-10% -$1.07M
BLUE
41
DELISTED
bluebird bio
BLUE
$8.9M 0.98%
5,404
+1,158
+27% +$2M
TMO icon
42
Thermo Fisher Scientific
TMO
$220B
$8.75M 0.96%
29,800
-200
-0.7% -$55.1K
OMCL icon
43
Omnicell
OMCL
$1.68B
$8.63M 0.95%
100,375
– –
CHRS icon
44
Coherus Oncology
CHRS
$196M
$8.62M 0.95%
390,000
-61,131
-14% -$1.06M
SGMO
45
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.55M 0.94%
793,957
-50,000
-6% -$532K
INCY icon
46
Incyte
INCY
$24.4B
$8.5M 0.94%
100,000
– –
GTHX
47
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$8.41M 0.93%
274,274
+62,105
+29% +$1.31M
AERI
48
DELISTED
Aerie Pharmaceuticals
AERI
$7.68M 0.85%
260,000
– –
STML
49
DELISTED
Stemline Therapeutics, Inc.
STML
$7.57M 0.83%
+493,999
New +$7.15M
DPLO
50
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$7.33M 0.81%
1,203,405
– –
1
2
3 4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2019 Portfolio in Review

As of Q2 2019, Rhenman & Partners Asset Management held 100 positions worth $908M, up 6.2% from $855M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $30.8M of net new capital in Q2 2019, opening 7 new positions and adding to 28 existing holdings. Its largest new stake was Horizon Bancorp: 1,087,656 shares worth $26.2M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Cigna, an estimated $9.95M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2019 buy was Horizon Bancorp: 1,087,656 shares worth $26.2M.
  • Rhenman & Partners Asset Management added most to Regeneron Pharmaceuticals in Q2 2019, an estimated $9.66M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2019 reduction was Cigna, cutting an estimated $9.95M.
  • Rhenman & Partners Asset Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019, selling an estimated $24.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $908M portfolio in Q2 2019.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 12 in Q2 2019.
  • Rhenman & Partners Asset Management's portfolio value rose 6.2% quarter-over-quarter to $908M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2019, filed 22 Jul 2019.